The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Open accessAbstract
Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death. Most cases of CRC are detected in Western countries, with its incidence increasing year by year. The probability of suffering from colorectal cancer is about 4%–5% and the risk for developing CRC is associated with personal features or habits such as age, chronic disease history and lifestyle. In this context, the gut microbiota has a relevant role, and dysbiosis situations can induce colonic carcinogenesis through a chronic inflammation mechanism. Some of the bacteria responsible for this multiphase process include Fusobacterium spp, Bacteroides fragilis and enteropathogenic Escherichia coli. CRC is caused by mutations that target oncogenes, tumour suppressor genes and genes related to DNA repair mechanisms. Depending on the origin of the mutation, colorectal carcinomas can be classified as sporadic (70%); inherited (5%) and familial (25%). The pathogenic mechanisms leading to this situation can be included in three types, namely chromosomal instability (CIN), microsatellite instability (MSI) and CpG island methylator phenotype (CIMP). Within these types of CRC, common mutations, chromosomal changes and translocations have been reported to affect important pathways (WNT, MAPK/PI3K, TGF-β, TP53), and mutations; in particular, genes such as c-MYC, KRAS, BRAF, PIK3CA, PTEN, SMAD2 and SMAD4 can be used as predictive markers for patient outcome. In addition to gene mutations, alterations in ncRNAs, such as lncRNA or miRNA, can also contribute to different steps of the carcinogenesis process and have a predictive value when used as biomarkers. In consequence, different panels of genes and mRNA are being developed to improve prognosis and treatment selection. The choice of first-line treatment in CRC follows a multimodal approach based on tumour-related characteristics and usually comprises surgical resection followed by chemotherapy combined with monoclonal antibodies or proteins against vascular endothelial growth factor (VEGF) and epidermal growth receptor (EGFR). Besides traditional chemotherapy, alternative therapies (such as agarose tumour macrobeads, anti-inflammatory drugs, probiotics, and gold-based drugs) are currently being studied to increase treatment effectiveness and reduce side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wan, Y., Li, T., Han, Y., Zhang, H., Lin, H. L., & Zhang, B. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4788 · Cited by 18
RetractedFree radicals and antioxidants in normal physiological functions and human disease
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M., & Telser, J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.07.001 · Cited by 14,269
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Diet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100 · cited 1×
“Many factors, such as antibiotic treatment or some types of diet, are known to be involved in the development of dysbiosis [139,148,149].”
BackgroundComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Human gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
Gupta, R. A., Shah, N., Wang, K. C., Kim, J., Horlings, H. M., Wong, D. J., Tsai, M.-C., Hung, T., Argani, P., Rinn, J. L., et al. (2010) · Nature · doi:10.1038/nature08975 · Cited by 5,218
Plant Polyphenols as Dietary Antioxidants in Human Health and Disease
Pandey, K. B., & Rizvi, S. I. (2009) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.2.5.9498 · Cited by 3,942
Antioxidant Activity and Total Phenolics in Selected Fruits, Vegetables, and Grain Products
Velioglu, Y. S., Mazza, G., Gao, L., & Oomah, B. D. (1998) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf9801973 · Cited by 3,841
Cited by
Action and function of Faecalibacterium prausnitzii in health and disease
Ferreira-Halder, C. V., Faria, A. V. D. S., & Andrade, S. S. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.09.011 · Cited by 471
Hibberd, A. A., Lyra, A., Ouwehand, A. C., Rolny, P., Lindegren, H., Cedgård, L., & Wettergren, Y. (2017) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2017-000145 · Cited by 373
The Role of p53 Signaling in Colorectal Cancer
Liebl, M. C., & Hofmann, T. G. (2021) · Cancers · doi:10.3390/cancers13092125 · Cited by 318
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
Yaghoubi, N., Soltani, A., Ghazvini, K., Hassanian, S. M., & Hashemy, S. I. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.105 · Cited by 299
Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer
Qu, R., Zhang, Y., Ma, Y., Zhou, X., Sun, L., Jiang, C., Zhang, Z., & Fu, W. (2023) · Advanced Science · doi:10.1002/advs.202205563 · Cited by 297
Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals
Gibiino, G., Lopetuso, L. R., Scaldaferri, F., Rizzatti, G., Binda, C., & Gasbarrini, A. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.03.016 · Cited by 278
Deng, X., Li, Z., Li, G., Li, B., Jin, X., & Lyu, G. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01607 · Cited by 114
Alvandi, E., Wong, W. K. M., Joglekar, M. V., Spring, K. J., & Hardikar, A. A. (2022) · BMC Medicine · doi:10.1186/s12916-022-02529-4 · Cited by 101
IGF2BP2 promotes the progression of colorectal cancer through a YAP‐dependent mechanism
Cui, J., Tian, J., Wang, W., He, T., Li, X., Gu, C., Wang, L., Wu, J., & Shang, A. (2021) · Cancer Science · doi:10.1111/cas.15083 · Cited by 90
Colon and rectal cancer: An emergent public health problem
Pinheiro, M., Moreira, D. N., & Ghidini, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i7.644 · Cited by 80
Wu, H., Ding, X., Hu, X., Zhao, Q., Chen, Q., Sun, T., Li, Y., Guo, H., Li, M., Gao, Z., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02189-x · Cited by 26
Artificial Intelligence in the Diagnosis of Colorectal Cancer: A Literature Review
Uchikov, P., Khalid, U., Kraev, K., Hristov, B., Kraeva, M., Tenchev, T., Chakarov, D., Sandeva, M., Dragusheva, S., Taneva, D., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14050528 · Cited by 22
Si, Y., Li, L., Zhang, W., Liu, Q., & Liu, B. (2022) · Oncology Reports · doi:10.3892/or.2022.8397 · Cited by 13
Bacteriophages, Antibiotics and Probiotics: Exploring the Microbial Battlefield of Colorectal Cancer
Volovat, C. C., Cosovanu, M. A., Ostafe, M.-R., Augustin, I. G., Volovat, C., Georgescu, B., & Volovat, S. R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167837 · Cited by 8
Metadata
- Authors
- Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-01-19
- Volume
- 18
- Issue
- 1
- Pages
- 197
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2579357550
- Cited by
- 1,525
- References
- 267
- FWCI
- 58.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.